Login to Your Account

FDA Reviews Solzira; XenoPort Exercises Co-Promote Option

By Trista Morrison

Tuesday, April 14, 2009
While the FDA reviews a new drug application for Solzira (gabapentin enacarbil) in restless legs syndrome, XenoPort Inc. exercised its option to co-promote the drug in the U.S. with partner GlaxoSmithKline plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription